Optimize Your Approach To mAb Development

By Kimberly Prohaska, PhD, senior scientist for research and development; Samantha Kupco, scientist research and development; and Manuel Matos, PhD, field application scientist, bioproduction group

As demand for monoclonal antibodies (mAbs) and their variants, e.g., bispecific antibodies and antibody drug conjugates, continues to grow, drug developers are looking to ensure robust and efficient process development approaches. Some of the critical areas of mAb process development include stable CHO cell line creation, optimized media and feed selection, and rapid downstream process development using resin high-throughput screening.

En route to manufacturing success, it is important to implement optimization to create efficiencies wherever possible. Optimization includes selecting CHO host cells strategically; identifying the media and feed, which will offer maximum growth and productivity while maintaining desired protein quality; and leveraging innovative resin high-throughput screening techniques for streamlined purification.

If you are looking to optimize your mAb process development, there are a wide range of options available. Consider how and where you can leverage strategic implementations to maximize cell growth and productivity while streamlining your processes. From there, identify suppliers that can deliver the starting materials and technologies to help your workflow thrive.